Difference between revisions of "Ferric carboxymaltose (Injectafer)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "[[Category:Drugs FDA" to "[[Category:FDA") |
Warner-admin (talk | contribs) m (Text replacement - "please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [https://online.lexi.com/lco/action/login UpToDate Lexidrug], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information" to "please refer to your preferred pharmacopeias or the prescribing information") |
||
| (6 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Colloidal iron (III) hydroxide in complex with carboxymaltose, a carbohydrate polymer that releases iron.<ref name="insert">[http://www.injectafer.com/pdf/pi.pdf Ferric carboxymaltose (Injectafer) package insert]</ref><ref>[[ | + | Class/mechanism: Colloidal iron (III) hydroxide in complex with carboxymaltose, a carbohydrate polymer that releases iron.<ref name="insert">[http://www.injectafer.com/pdf/pi.pdf Ferric carboxymaltose (Injectafer) package insert]</ref><ref>[[:File:Ferriccarboxymaltose.pdf | Ferric carboxymaltose (Injectafer) package insert (locally hosted backup)]]</ref><ref>[http://www.injectafer.com/ Injectafer manufacturer's website]</ref> |
<br>Route: IV | <br>Route: IV | ||
<br>Extravasation: no information | <br>Extravasation: no information | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.<ref name="insert"></ref> |
==Patient drug information== | ==Patient drug information== | ||
| Line 10: | Line 10: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | * | + | *2013-07-25: Approved for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron. |
| − | + | *2013-07-25: Approved for the treatment of iron deficiency anemia in adult patients who have non-dialysis-dependent chronic kidney disease. | |
| − | * | ||
==Also known as== | ==Also known as== | ||
| Line 22: | Line 21: | ||
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
[[Category:Hematology medications]] | [[Category:Hematology medications]] | ||
| − | [[Category:Iron]] | + | [[Category:Iron replacement]] |
[[Category:FDA approved in 2013]] | [[Category:FDA approved in 2013]] | ||
Latest revision as of 01:05, 29 June 2024
General information
Class/mechanism: Colloidal iron (III) hydroxide in complex with carboxymaltose, a carbohydrate polymer that releases iron.[1][2][3]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.[1]
Patient drug information
History of changes in FDA indication
- 2013-07-25: Approved for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron.
- 2013-07-25: Approved for the treatment of iron deficiency anemia in adult patients who have non-dialysis-dependent chronic kidney disease.
Also known as
- Brand name: Injectafer